Literature DB >> 24476443

Tiotropium and the risk of death in COPD.

Katia M C Verhamme, Nico van Blijderveen, Miriam C J M Sturkenboom.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24476443     DOI： 10.1056/NEJMc1314411

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  Response to Wise et al. (Tiotropium safety in real life populations).

Authors:  Sven Schmiedl; Petra Thürmann; Rainald Fischer; Dominik Rottenkolber; Marietta Rottenkolber
Journal:  Br J Clin Pharmacol       Date:  2016-05-20       Impact factor: 4.335

2.  Overall and Cardiovascular Safety of Aclidinium Bromide in Patients With COPD: A Pooled Analysis of Six Phase III, Placebo-Controlled, Randomized Studies.

Authors:  Kenneth R Chapman; Ekkehard Beck; Daniel Alcaide; Esther Garcia Gil
Journal:  Chronic Obstr Pulm Dis       Date:  2015-12-22

Review 3.  Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.

Authors:  Gerard J Criner; Jean Bourbeau; Rebecca L Diekemper; Daniel R Ouellette; Donna Goodridge; Paul Hernandez; Kristen Curren; Meyer S Balter; Mohit Bhutani; Pat G Camp; Bartolome R Celli; Gail Dechman; Mark T Dransfield; Stanley B Fiel; Marilyn G Foreman; Nicola A Hanania; Belinda K Ireland; Nathaniel Marchetti; Darcy D Marciniuk; Richard A Mularski; Joseph Ornelas; Jeremy D Road; Michael K Stickland
Journal:  Chest       Date:  2015-04       Impact factor: 9.410

4.  Tiotropium Respimat(®) vs. HandiHaler(®): real-life usage and TIOSPIR trial generalizability.

Authors:  Sven Schmiedl; Rainald Fischer; Luisa Ibanez; Joan Fortuny; Petra Thürmann; Elena Ballarin; Pili Ferrer; Monica Sabaté; Dominik Rottenkolber; Roman Gerlach; Martin Tauscher; Robert Reynolds; Joerg Hasford; Marietta Rottenkolber
Journal:  Br J Clin Pharmacol       Date:  2015-12-23       Impact factor: 4.335

Review 5.  Tiotropium Respimat(®) Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

Review 6.  Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease.

Authors:  Marc Miravitlles; David Price; Klaus F Rabe; Hendrik Schmidt; Norbert Metzdorf; Bartolome Celli
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-03-16

7.  Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.

Authors:  Anthony D D'Urzo; Edward M Kerwin; Kenneth R Chapman; Marc Decramer; Robert DiGiovanni; Peter D'Andrea; Huilin Hu; Pankaj Goyal; Pablo Altman
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-08-11

Review 8.  Long-term safety of tiotropium delivered by Respimat® SoftMist™ Inhaler: patient selection and special considerations.

Authors:  Ching Kuo Tan; Gui Quan Say; James B Geake
Journal:  Ther Clin Risk Manag       Date:  2016-09-21       Impact factor: 2.423

9.  Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies.

Authors:  Craig LaForce; Eric Derom; Ulrich Bothner; Isabel M Kloer; Matthias Trampisch; Roland Buhl
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-06-01

10.  Major comorbidities lead to the risk of adverse cardiovascular events in chronic obstructive pulmonary disease patients using inhaled long-acting bronchodilators: a case-control study.

Authors:  Yen-Fu Chen; Yi-Ching Cheng; Chien-Hong Chou; Chung-Yu Chen; Chong-Jen Yu
Journal:  BMC Pulm Med       Date:  2019-12-03       Impact factor: 3.317
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.